JPH06219953A - Medicine for preventing and improving diarrhea, food for preventing and improving diarrhea and feed for preventing and improving scours - Google Patents
Medicine for preventing and improving diarrhea, food for preventing and improving diarrhea and feed for preventing and improving scoursInfo
- Publication number
- JPH06219953A JPH06219953A JP5029602A JP2960293A JPH06219953A JP H06219953 A JPH06219953 A JP H06219953A JP 5029602 A JP5029602 A JP 5029602A JP 2960293 A JP2960293 A JP 2960293A JP H06219953 A JPH06219953 A JP H06219953A
- Authority
- JP
- Japan
- Prior art keywords
- diarrhea
- improving
- preventing
- food
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 88
- 235000013305 food Nutrition 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000002245 particle Substances 0.000 claims abstract description 21
- 230000006872 improvement Effects 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 230000003449 preventive effect Effects 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229920002488 Hemicellulose Polymers 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 4
- 239000000843 powder Substances 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 14
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 12
- 239000001913 cellulose Substances 0.000 description 11
- 229920002678 cellulose Polymers 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 235000021056 liquid food Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 230000000112 colonic effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 235000020888 liquid diet Nutrition 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical group 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 3
- 244000235858 Acetobacter xylinum Species 0.000 description 3
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 210000003736 gastrointestinal content Anatomy 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 241000589220 Acetobacter Species 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 229920001340 Microbial cellulose Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 101100166200 Caenorhabditis elegans cpz-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010061549 Sensation of foreign body Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020882 elemental diet Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、経腸栄養剤、濃厚栄養
流動食などの投与時あるいは抗生物質など、医薬の投与
時に、屡々、発生する下痢の予防および改善に有効な、
経口投与可能な予防改善剤、下痢予防改善食品及び下痢
予防改善飼料に関する。FIELD OF THE INVENTION The present invention is effective for the prevention and improvement of diarrhea that often occurs at the time of administration of enteral nutritional supplements, concentrated nutrient liquid foods, etc., or administration of medicines such as antibiotics.
The present invention relates to an orally administrable preventive / improving agent, a diarrhea-preventing / improving food and a diarrhea-preventing / improving feed.
【0002】[0002]
【従来の技術】経腸栄養剤、濃厚栄養流動食、成分栄養
剤(エレメンタル ダイエット)等の高栄養・低残渣食
の投与時あるいは抗生物質などの医薬の投与時には、被
投与者の腸内菌叢の変化により、屡々、下痢の症状が発
生することが知られている。この種の下痢は、吸収され
ずに腸内に残留する摂取食物に由来する残渣固形分の減
少、あるいは特に経口抗生物質または胆汁排泄型の静注
抗生物質の投与時に発生する腸内微生物の顕著な減少に
起因する場合が多い。何れの場合にあっても腸内の自由
水の相対的増加に起因して、糞便の性状が水様、泥様に
変化して、下痢の症状を呈するに至る。2. Description of the Related Art Enteric bacteria of a recipient when a high-nutrition / low-residue diet such as an enteral nutritional supplement, a concentrated nutrient liquid diet, a component nutritional supplement (elemental diet), or a drug such as an antibiotic is administered. It is known that diarrhea often occurs due to changes in the flora. This type of diarrhea is caused by a decrease in residual solids derived from ingested food that is not absorbed and remains in the intestine, or by remarkable intestinal microorganisms that occur especially when oral antibiotics or bile excretion-type intravenous antibiotics are administered. Often due to a large decrease. In any case, due to the relative increase in free water in the intestine, the properties of feces change to watery or mud-like, leading to diarrhea.
【0003】上記の機作に注目して、腸内容中の固形分
を増量せしめることにより、相対的に自由水を減少せし
め、糞便の性状を正常ならしめる試みが行われてきた。
また、固形分の増量のために、経口投与可能であり、か
つ、難消化性あるいは難腸吸収性物質を単独にあるいは
食餌に添加して投与されてきた。そして同物質としては
各種の水溶性繊維、例えばペクチン、メトキシペクチ
ン、ガラクトマンナン、アルギン酸、同塩、寒天、カル
ボキシメチル セルロ−ス、同塩またはこれらの物質を
含有する食品あるいは各種の非水溶性繊維、例えばセル
ロ−ス粉末、ヘミセルロ−ス粉末、これらの混合物が使
用されている。With attention paid to the above-mentioned mechanism, attempts have been made to increase the solid content in the intestinal contents to relatively reduce free water and normalize the properties of feces.
Further, in order to increase the solid content, oral administration is possible, and an indigestible or intestinal absorbable substance has been administered alone or in the diet. Examples of the substance include various water-soluble fibers, such as pectin, methoxypectin, galactomannan, alginic acid, the same salt, agar, carboxymethyl cellulose, the same salt or foods containing these substances or various non-water-soluble fibers. , For example, cellulose powder, hemicellulose powder, and mixtures thereof.
【0004】しかしながら、上記の物質の投与に対し
て、被投与者の生理的あるいは心理的抵抗ないし困難は
避け難く、投与時にたとえ僅少であれ、異物感を伴う場
合には、有効な程度の量を投与することは不可能であっ
た。また、これらの物質の投与有効量は予想外に多量で
あり、被投与者に心理的強制を負担せしめてきた。さら
に、被投与者の腸内環境は個別に相違し、特定の被投与
者に適合する投与物質の種類および投与量を事前に決定
することは困難であった。However, the physiological or psychological resistance or difficulty of the recipient to the administration of the above substances is unavoidable, and when the administration is accompanied by a slight foreign body sensation, it is effective. Was impossible to administer. In addition, the effective doses of these substances are unexpectedly large, which imposes psychological compulsion on the recipient. Furthermore, the intestinal environment of the recipient differs individually, and it has been difficult to determine in advance the type and dose of the substance to be administered that is suitable for the particular recipient.
【0005】また、非水溶性繊維を投与した時に、どの
ような状態で腸内に存在する場合に、最大限の効果を認
めるかについての知見に関しても、未だ、充分な知見は
得られていない。[0005] In addition, regarding the knowledge as to what state the maximum effect is observed when the water-insoluble fiber is administered in the intestine, sufficient knowledge has not yet been obtained. .
【0006】[0006]
【発明が解決しようとする課題】本発明者らは、上記の
従来から存在していた問題点を再検討し、さらに従来か
ら使用されている種々の物質に関しても新たな見地か
ら、鋭意、検討を加え、後記に説明する動物実験ならび
に臨床試験により得た新たな知見に基づき、下痢予防改
善剤、下痢予防改善食品及び下痢予防改善飼料に関する
発明を完成した。DISCLOSURE OF THE INVENTION The present inventors reexamined the above-mentioned problems existing in the past, and further studied various substances which have been conventionally used from a new viewpoint. In addition, based on new findings obtained from animal experiments and clinical tests described below, the invention relating to a diarrhea prevention / improvement agent, a diarrhea prevention / improvement food and a diarrhea prevention / improvement feed was completed.
【0007】即ち、本発明は、上記の従来から使用され
てきた下痢の予防剤および改善剤ないし下痢症状の予防
および改善、治療方法における問題点を解消し、被投与
者に容易に受容され、可及的少量で最大限の効果を期待
できる、かつ、容易に調製可能な下痢予防改善用の経口
投与可能な下痢予防改善剤、下痢予防改善食品及び下痢
予防改善飼料を提供することにある。That is, the present invention solves the problems in the above-mentioned conventionally used preventive agents and ameliorating agents for diarrhea, prevention and amelioration of diarrhea symptoms, and treatment methods, and is easily accepted by the recipient. An object is to provide an orally administrable diarrhea prevention-improving agent, a diarrhea prevention-improving food and a diarrhea prevention-improving feed, which can be expected to be maximally effective in the smallest possible amount and can be easily prepared.
【0008】[0008]
【課題を解決するための手段】本発明に係る下痢予防改
善剤では、セルロース粉末を有効成分とするものであ
り、好ましくは粒子径200ミクロン以下、5ミクロン
以上のセルロース粉末を有効成分とするものである。更
に好ましくは、粒径200ミクロン以下、5ミクロン以
上のセルロース粉末を全セルロース粉末の75%以上含
むものである。The diarrhea preventive and ameliorating agent according to the present invention comprises a cellulose powder as an active ingredient, preferably a cellulose powder having a particle diameter of 200 microns or less and 5 microns or more as an active ingredient. Is. More preferably, cellulose powder having a particle size of 200 microns or less and 5 microns or more is contained at 75% or more of the total cellulose powder.
【0009】更に、本発明では、前記セルロ−ス粉末と
して、植物由来であるもの、又は、微生物由来であるも
のを開示する。また、前記セルロース粉末がヘミセルロ
−スを含有するものも開示する。Further, in the present invention, as the cellulose powder, a plant-derived powder or a microbial-derived powder is disclosed. Also disclosed is one in which the cellulose powder contains hemicellulose.
【0010】また更に、本発明では、前述の下痢予防改
善剤を分散・配合させた下痢予防改善剤、好ましくは前
述の下痢予防改善剤を均一に分散・配合させた下痢予防
改善剤だけでなく、前述の下痢予防改善剤を食品中に分
散・配合させた下痢予防改善食品、好ましくは前述の下
痢予防改善剤を食品中に均一に分散・配合させた下痢予
防改善食品、及び、前述の下痢予防改善剤を飼料中に分
散・配合させた下痢予防改善飼料、好ましくは前述の下
痢予防改善剤を飼料中に均一に分散・配合させた下痢予
防改善飼料をも開示する。Furthermore, in the present invention, not only a diarrhea prevention-improving agent in which the above-mentioned diarrhea-preventing / improving agent is dispersed / blended, preferably a diarrhea-preventing / improving agent in which the above-mentioned diarrhea-preventing / improving agent is uniformly dispersed / blended is used. , A diarrhea prevention-improving food in which the above-mentioned diarrhea prevention-improving agent is dispersed / blended in food, preferably a diarrhea-prevention-improving food in which the above-mentioned diarrhea-preventing / improving agent is uniformly dispersed / blended in food, and the above-mentioned diarrhea Also disclosed is a diarrhea-prevention-improving feed in which a preventive-improving agent is dispersed / blended in a feed, preferably a diarrhea-prevention-improving feed in which the above-mentioned diarrhea-preventing / improving agent is uniformly dispersed / blended in a feed.
【0011】[0011]
【作用】従来より下痢改善剤あるいは便秘改善剤とし
て、セルロ−ス粉末は使用されてきたが、特に低残渣栄
養食の投与時あるいは抗生物質投与時に発生する下痢の
予防または改善に関する特定の粒径範囲及び動粒径分布
範囲のセルロース粉末についての効果を確認した知見は
ない。Although cellulose powder has been used as a diarrhea-improving agent or a constipation-improving agent, it has a specific particle size for preventing or ameliorating diarrhea that occurs especially when a low-residue nutritional diet or antibiotics is administered. There is no finding confirming the effect of the cellulose powder in the range and the dynamic particle size distribution range.
【0012】本発明者らは、従来のセルロ−ス粉末の効
果に関する認識に疑問を懐き、種々の実験を行い、それ
らの結果を分析、検討してセルロ−ス粉末の下痢の症状
の改善に関する効果は、意外にも、 1.セルロ−スの種類の如何によるのではないこと、 2.セルロース粉末粒子の粒径の分布状態に直接の関係
を有すること、 3.その粒子径の範囲は200ミクロン以下、5ミクロ
ン以上であること、 4.有効なセルロ−ス粉末は、この範囲の粒子を主要区
分となし、75%以上含むこと、 5.さらに、その粒度分布は、比較的、明確であり、特
に被投与者に異物感を懐かせる200ミクロンを大幅に
越える粒子の存在は好ましくなく、最大限5%を越えな
いこと、また、5ミクロン未満の微粒子が20%以上存
在する場合には、口腔内のレオロジ−感が異常となり、
粗大粒子の場合と同様に好ましくないこと、 6.投与したセルロース粉末が腸内で可及的均一に分散
して存在する時は、最も効果的な結果を得ること、 を発見した。The present inventors questioned the recognition of the effect of the conventional cellulose powder, conducted various experiments and analyzed and examined the results to improve the symptoms of diarrhea of the cellulose powder. Surprisingly, the effects are: 1. It does not depend on the type of cellulose, 2. Having a direct relationship with the distribution of the particle size of the cellulose powder particles, 3. The particle size range is 200 microns or less and 5 microns or more; 4. The effective cellulose powder contains particles in this range as a main category and contains 75% or more of the particles. Furthermore, the particle size distribution is relatively clear, and the presence of particles significantly exceeding 200 microns, which makes the recipient feel a foreign body, is not preferable, and it should not exceed 5% at the maximum. If less than 20% of fine particles are present, the rheology in the oral cavity becomes abnormal,
5. Not as preferable as the case of coarse particles, 6. It has been found that the most effective results are obtained when the administered cellulose powder is present in the intestine as uniformly dispersed as possible.
【0013】従って、本発明では、セルロース粉末を有
効成分とするものであり、好ましくは、粒子径200ミ
クロン以下、5ミクロン以上のセルロース粉末を有効成
分とするものである。更に好ましくは、粒径200ミク
ロン以下、5ミクロン以上のセルロース粉末を全セルロ
ース粉末の75%以上含むものであるため、被投与者に
容易に受容され、可及的少量で最大限の効果を期待で
き、かつ、容易に調製可能な下痢予防改善用の経口投与
可能な下痢予防改善剤が得られる。Therefore, in the present invention, cellulose powder is used as an active ingredient, and preferably cellulose powder having a particle diameter of 200 microns or less and 5 microns or more is used as an active ingredient. More preferably, it contains 75% or more of the cellulose powder having a particle size of 200 microns or less and 5 microns or more of the total cellulose powder, so that it is easily accepted by the recipient and the maximum effect can be expected with the smallest possible amount. In addition, an orally administrable diarrhea-preventing and improving agent for improving and preventing diarrhea that can be easily prepared can be obtained.
【0014】尚、本発明の予防改善剤は、経口投与が可
能であることが必要であるが、被投与者が懐きがちな異
物感、薬物感を回避するために、通常の食事、濃厚栄養
流動食、経腸栄養剤などに可及的均一に混合して投与す
ることがのぞましい。もちろん、被投与者にかかる心理
的な負担がない時は、セルロ−ス粉末を粉末状態のま
ま、懸濁シロップとして、あるいは易分解性、易分解性
の錠剤として投与することも可能であるが、投与後、腸
内容物中に速やかにセルロ−ス粉末が均一に分布する場
合に最大限の効果が認められるので、投与前に前記の経
口投与物中に均一に混合した調製物として投与するのが
適当である。また、食事あるいは医薬の投与により下痢
の発生が予想できる場合は、予め本発明の予防改善剤を
投与することは、下痢の予防に有効である。The preventive-improving agent of the present invention needs to be orally administrable. However, in order to avoid the foreign body sensation and drug sensation that the recipient tends to feel, normal diet and concentrated nutrition are required. It is advisable to administer it in a liquid diet, enteral nutrient, etc. as uniformly mixed as possible. Of course, when there is no psychological burden on the recipient, it is possible to administer the cellulose powder in a powder state as a suspension syrup, or as a readily degradable or easily degradable tablet. Since the maximum effect is observed when the cellulosic powder is rapidly and uniformly distributed in the intestinal contents after administration, it is administered as a preparation uniformly mixed with the above oral administration before administration. Is appropriate. Further, when the occurrence of diarrhea can be predicted by the administration of meals or drugs, pre-administration of the preventive and amelioration agent of the present invention is effective for the prevention of diarrhea.
【0015】セルロ−ス粉末の投与量は、被投与者の症
状および一般状態により決定されるが、成人一人当た
り、5g以上40g以下が適当である。また、幼年者ま
たは老年者は前記量の1/2でよい。さらに投与は、最
初、少量から開始し、症状の改善状態を観察しつつ増量
または減少せしめる。なお、この範囲を越える投与は被
投与者に異物感を与え、場合によっては下痢の症状を悪
化せしめることもある。また、範囲以下の少量の投与で
は効果は認め難い。さらに、前記の粒度範囲を大幅に越
えるセルロ−ス粉末を、有効量投与しようとしても、一
般には、心理的抵抗が大きく、投与は困難となる。ま
た、投与時にセルロース粉末を均一状態に分散した調整
物を調整することも困難となる。The dose of the cellulose powder is determined depending on the symptoms and general condition of the recipient, but is preferably 5 g or more and 40 g or less per adult. In addition, the amount of infants or the elderly may be ½ of the above amount. Further, the administration is started at a small dose at first and then the dose is increased or decreased while observing the improvement state of symptoms. Administration exceeding this range may give the recipient a feeling of foreign body, and in some cases may exacerbate the symptoms of diarrhea. In addition, it is difficult to recognize the effect when administered in a small amount below the range. Furthermore, even if an attempt is made to administer an effective amount of cellulose powder that greatly exceeds the above-mentioned particle size range, psychological resistance is generally large and administration becomes difficult. Moreover, it becomes difficult to prepare a preparation in which cellulose powder is uniformly dispersed at the time of administration.
【0016】投与に当たっては、投与の都度、セルロ−
ス粉末を食事、流動食、栄養剤などに均一に強制混合し
て新たに調製することが望ましいが、調整後、相当長時
間に亙って均一状態を保ち得る場合には、数回分の投与
量をまとめて調製してもよい。また、セルロース粉末を
粉末状態、懸濁シロップ、易分解性の錠剤として投与す
る場合にあっても、投与後、腸内容物中に速やかにセル
ロース粉末が均一に分布するように、適当な分散媒ある
いは分散助剤と均一に混合、分散した状態で投与すべき
である。[0016] In administration, cellulosic
It is desirable to prepare a fresh powder by uniformly mixing the powdered powder with food, liquid food, nutritional supplement, etc., but if it is possible to maintain the homogeneity for a considerable time after adjustment, administer several doses. The amounts may be prepared in bulk. In addition, even when the cellulose powder is administered in the form of powder, suspension syrup, or easily degradable tablet, a suitable dispersion medium should be provided so that the cellulose powder is quickly and uniformly distributed in the intestinal contents after administration. Alternatively, it should be administered in the state of being uniformly mixed and dispersed with a dispersion aid.
【0017】また、本発明で使用するセルロ−ス粉末
は、通常、容易に想到し得るセルロ−ス粉末、例えば、
濾紙粉末、医薬添加用精製セルロ−ス粉末、製剤用精製
セルロ−ス粉末、通常食品または機能性食品添加用精製
セルロ−ス、精製レ−ヨン粉末の他に、ヘミセルロ−ス
を相当程度含有する未精製セルロ−ス、すなわち、小麦
ふすま粉末、大麦穀粒皮粉末、大豆種皮粉末、コ−ン穀
粒皮粉末、綿花リンタ−粉末、多繊維野菜粉末、果実皮
精製粉末などを含む。また、未精製セルロ−ス粉末に
は、ヘミセルロ−スの他に若干量のペクチン、キチン、
リグニンなどを含有する場合をも含まれる。さらに、こ
れらの植物由来のセルロ−ス粉末の他に微生物、例えば
酢酸菌、アセトバクタ− キシリナム (Acetob
acterxylinum) の生産する微生物由来の
セルロ−ス粉末も含む。The cellulose powder used in the present invention is usually an easily conceivable cellulose powder, for example,
In addition to filter paper powder, purified cellulose powder for pharmaceutical additives, purified cellulose powder for pharmaceutical preparations, purified cellulose powder for addition of ordinary foods or functional foods, purified rayon powder, it contains a considerable amount of hemicellulose. It includes unrefined cellulose, that is, wheat bran powder, barley kernel powder, soybean seed powder, corn kernel powder, cotton linter powder, multifilament vegetable powder, fruit powder refined powder and the like. In addition, in the unpurified cellulose powder, in addition to hemicellulose, a small amount of pectin, chitin,
It also includes the case of containing lignin and the like. Furthermore, in addition to the cellulosic powder derived from these plants, microorganisms such as acetic acid bacteria and Acetobacter xylinum (Acetob) are also available.
cellulosic powder derived from a microorganism produced by Acterxylinum).
【0018】[0018]
【実施例】(実施例 1、動物実験 1) 8週令のSD系雄ラット
を、1週間、飲水カラムを使用して、濃厚栄養流動食
「メディエフ リキッド[味の素(株)製品]」を40
Kcal/日の制限給食条件下に飼育した。6日後に
供試動物の全頭に、水様便または泥様便の発生を認め
た。7日後に動物を各群5頭より成る次の5群に分別
し、対照群以外の動物には、群名に示す添加物を上記の
流動食に対し5重量%添加した飼料を、前記と同様の給
餌条件下に供与しつつ、次の1週間、飼育した。なお、
飼料の調製は毎日午後4時に行い、直ちに給餌した。
尚、調製には上記の流動食および所定量の添加物を、氷
冷下にワ−リング・ブレンダ−で1分間撹拌する方法に
よった。Examples (Example 1, Animal Experiments 1) SD male rats aged 8 weeks were treated with a concentrated nutrient liquid diet “Mediflu Liquid [Ajinomoto Co., Inc. product]” 40 for 1 week using a drinking water column.
The animals were bred under a restricted diet condition of Kcal / day. After 6 days, the occurrence of watery feces or mud-like feces was observed in all the test animals. After 7 days, the animals were divided into the following 5 groups, each group consisting of 5 animals, and the animals other than the control group were treated with the feed containing 5% by weight of the additive shown in the group name in the liquid diet. The animals were raised for the next week while feeding under the same feeding conditions. In addition,
The feed was prepared daily at 4 pm and fed immediately.
The preparation was carried out by stirring the above liquid food and a predetermined amount of additives with a Waring blender for 1 minute while cooling with ice.
【0019】実験動物群の構成および添加物: 1.対照群−−−−−−添加物なし 2.ペクチン群−−−−メトキシペクチンを主成分とす
る多糖。食品添加物純度。M.W.,50〜10.0万 3.ガラクトマンナン群−−「こんにゃく」に由来する
多糖。機能性食品添加用。M.W.,0.2〜0.3万 4.セルロ−ス群 −−−「パルプ」に由来する植物繊
維粉末。200ミクロン〜5ミクロン区分、90%以
上。食品添加物純度。M.W.,1.0〜10.0万 5.人参粉末群−−−−「カロッテ」 [商品名、味の
素(株)製品]。含有多糖のM.W.,60.0〜18
0.0万 (M.W.:添加物に含有する多糖の平均分子量分布)Composition of experimental animals and additives: 1. Control group ----- no additives 2. Pectin group --- A polysaccharide whose main component is methoxypectin. Food additive purity. M. W. , 50 to 10 million 3. Galactomannan group --- A polysaccharide derived from "konjac". For adding functional foods. M. W. , 0.2 to 30 thousand 4. Cellulose group --- A vegetable fiber powder derived from "pulp". 200 to 5 micron classification, 90% or more. Food additive purity. M. W. , 1.0 to 10 million 5. Carrot powder group --- "Carotte" [trade name, product of Ajinomoto Co., Inc.]. The polysaccharide containing M. W. , 60.0-18
0.0 million (MW: average molecular weight distribution of polysaccharide contained in additive)
【0020】実験結果は次の通り: 1.対照群−−−−−−下痢の症状さらに悪化。実験期
間中、全日、全頭が水様便または泥様便 2.ペクチン群−−−−下痢の症状の改善を認め得ず。
5頭中、3頭はむしろ悪化した 3.ガラクトマンナン群−−下痢の症状の改善を認め得
ず。5頭中、4頭はむしろ悪化した。 4.セルロ−ス群−−−下痢の症状の改善は顕著。最終
の2日間は全5頭とも正常便。投与後2日目より改善効
果を認める 5.人参粉末群 −−−多少の改善効果を認める。最終
の2日間には、各日2〜3頭が正常便The experimental results are as follows: Control group -------- Symptoms of diarrhea worsened. During the experimental period, all heads are watery or mud-like stools on all days 2. Pectin group --- No improvement in diarrhea symptoms was observed.
3 out of 5 were worse. Galactomannan group: No improvement in diarrhea symptoms was observed. Four out of five became worse. 4. Cellulose group --- Improvement of diarrhea symptoms is remarkable. All 5 were normal stools during the last 2 days. 4. From the second day after administration, an improvement effect is recognized 5. Carrot powder group --- Some improvement effect is recognized. 2 to 3 normal stools each day during the last 2 days
【0021】(実施例 2、動物実験 2)8週令のS
D系ラットを、1週間、抗生物質「セフォペラゾン ナ
トリウム;CPZ」水溶液を、CPZ1mg/100g
飼料相当に添加して、半湿潤状態となした実験用飼料
「CRF−1」 [商品名、オリエンタル酵母(株)
製]により、自由摂食条件下に飼育した。実験開始後、
2日目には約30%の動物に水様便、泥様便が発生し、
7日目には全頭に顕著な下痢の症状が認められた。7日
目に動物を、各群5頭より成る次の4群に分別し、対照
群以外の動物には、群名に示す添加物を上記の飼料に対
し、乾物当たり5重量%添加、混合した飼料を上記と同
様の摂食条件下に供与しつつ、次の1週間を飼育した。
なお、飼料の調製は毎日午後4時に行い、直ちに給餌し
た。また、新たな給餌を行う際に食残量を測定した。 (Example 2, animal experiment 2) S of 8 weeks old
For 1 week, D strain rats were treated with the antibiotic "cefoperazone sodium; CPZ" aqueous solution, CPZ 1 mg / 100 g
Experimental feed "CRF-1", which was added in an amount equivalent to that of the feed and was in a semi-wet state [trade name, Oriental Yeast Co., Ltd.
The product was raised under free feeding conditions. After the experiment started,
On the second day, about 30% of animals develop watery or mud-like stools,
On the 7th day, all diarrhea showed marked diarrhea. On the 7th day, the animals were sorted into the following 4 groups, each consisting of 5 animals, and for the animals other than the control group, the additives shown in the group name were added to the above feed at 5% by weight per dry matter and mixed. The fed feed was fed under the same feeding conditions as above, and the animals were bred for the next week.
The feed was prepared every day at 4:00 pm and fed immediately. In addition, the amount of food remaining was measured when new feeding was performed.
【0022】実験動物群の構成および添加物: 1.対照群−−−−−添加物なし 2.乳酸菌群−−−−乳酸菌生菌体(*1) 3.大豆オリゴ糖群−大豆オリゴ糖粉末(*2) 4.セルロ−ス群−−「バイオセルロ−ス」粉末、20
0ミクロン〜5ミクロン区分 90%以上(*3) (*1) 市販のプレイン ヨ−グルトより分離した乳
酸菌をグルコ−ス添加牛乳ホエイ培地に培養、遠心分
離、集菌した湿潤生菌体。 (*2) 大豆分離蛋白の製造時に副生する大豆ホエイ
より分離したオリゴ糖区分の乾燥粉末。 (*3) 酢酸菌、アセトバクタ− キシリナム(Ac
etobacter xylinum)を蔗糖培地に撹
拌条件下、培養し生成したセルロ−ス膜を分取、乾燥
後、液体窒素冷却下に高速粉砕して取得した微生物セル
ロ−ス粉末。Composition of experimental animals and additives: 1. Control group ----- no additives 2. Lactic acid bacteria group --- Live lactic acid bacteria (* 1) 3. Soybean oligosaccharide group-soybean oligosaccharide powder (* 2) 4. Cellulose group- "Biocellulose" powder, 20
0 micron to 5 micron classification 90% or more (* 3) (* 1) Wet viable cells obtained by culturing, centrifuging and collecting the lactic acid bacteria separated from commercially available plain yogurt in a glucose whey medium supplemented with milk. (* 2) Dry powder of oligosaccharides separated from soybean whey, which is a by-product of soybean isolated protein production. (* 3) Acetobacter, Acetobacter-Xylinum (Ac
Microbial cellulosic powder obtained by culturing etohobacter xylinum) in a sucrose medium under stirring conditions, collecting the resulting cellulose membrane, drying, and crushing at high speed under cooling with liquid nitrogen.
【0023】実験結果は次の通り: 1.対照群−−−−−下痢症状さらに悪化。実験期間
中、全日、全頭が多量の水様便または泥様便。実験開始
後2日目に1頭、4日目に2頭が斃死。結腸内容物は全
頭とも泥様便、粘膜の付着顕著。 2.乳酸菌群−−−−下痢症状の改善は顕著ならず。た
だし、1頭のみ軟便までに回復。同動物以外の4頭の結
腸内容物は全て泥様便。 3.大豆オリゴ糖群−下痢症状の改善は顕著ならず。た
だし、1頭のみ軟便までに回復。同動物以外の4頭の結
腸内容物は全て泥様便。 4.セルロ−ス群−−下痢症状の改善顕著。最終日には
全5頭とも正常便。実験開始後 2日目以降に効果を認
める。結腸内容物は全頭とも固形の正常便。The experimental results are as follows: Control group -------- Diarrhea symptoms worsened. During the experiment period, all the animals have a large amount of watery or mud-like stools all day. One animal died two days after the start of the experiment and two died on the fourth day. The colonic contents of all the heads were mud-like stool and the adhesion of mucous membrane was remarkable. 2. Lactobacillus group ----- Improvement of diarrhea symptoms is not remarkable. However, only one animal recovered to loose stool. Except for the same animal, all 4 colonic contents were mud-like stools. 3. Soybean oligosaccharide group-Diarrhea is not significantly improved. However, only one animal recovered to loose stool. Except for the same animal, all 4 colonic contents were mud-like stools. 4. Cellulose group--Remarkably improved diarrhea. On the last day, all 5 were normal stools. The effect is recognized from the second day after the start of the experiment. All colonic contents are solid normal stools.
【0024】(対照例 1、動物実験 3)実施例1の
4.セルロ−ス群に投与した植物繊維粉末、200ミク
ロン〜5ミクロン区分を分取した残余の篩分未通過区分
を実施例1、4.セルロース群で使用の同一組成の濃厚
栄養流動食に添加し、同様の調製物を取得した。実施例
1と同一条件下に飼育し、水様便または泥様便を呈して
いるラット10頭に、この調製物を供与しつつ、次の1
週間、飼育した。 (Control Example 1, Animal Experiment 3) 4. The plant fiber powder administered to the cellulosic group, the remaining sieve-unpassed section obtained by separating the 200-micron to 5-micron section were used in Examples 1, 4. A similar preparation was obtained by adding to the concentrated nutrient liquid food of the same composition used in the cellulose group. While providing this preparation to 10 rats bred under the same conditions as in Example 1 and exhibiting watery or mud-like stools, the following 1
It was raised for a week.
【0025】実験期間中、全日、全頭が水様便または泥
様便を呈しており、下痢の改善効果は認め得ず。1週間
の実験飼育の後、下痢症状の顕著な5頭を剖見の結果、
結腸内容物は5頭とも水様便であり、粘膜の付着は顕著
であった。During the experimental period, all heads exhibited watery or mud-like stools all day, and no improvement effect on diarrhea was observed. After 1 week of experimental breeding, the results of autopsy of 5 diarrhea symptoms
All 5 colonic contents were watery stools, and the mucosal attachment was remarkable.
【0026】(実施例 3、臨床試験 1)胃を亜全
摘、セファロスポリン系抗生物質投与中の45才の男子
患者は、術前より継続して軟便、次いで水様便の下痢症
状を呈していた。術後、第3日以降、200ミクロン以
下5ミクロン以上の粒径を有する食品添加物純度のセル
ロ−ス粉末(「パルプ」精製物)を脱脂粉乳その他必要
な栄養成分を主成分とする栄養流動食に、無菌条件下、
均一に添加、混合後、経口投与した。セルロ−スの投与
量は第3日目、9g/日、第4日目以降は12g/日で
あった。第5日以降に下痢症状の改善が認められ、第7
日には正常便に類する軟便状態に回復した。また、下痢
症状の改善に伴い、一般所見の改善も認められた。 Example 3 Clinical Trial 1 A 45-year-old male patient who underwent subtotal gastrectomy and administration of cephalosporin antibiotics had diarrhea symptoms of soft stool and then watery feces continuously before the operation. I was presenting. After the 3rd day after the operation, a food additive-purified cellulose powder (“pulp” refined product) having a particle size of 200 μm or less and 5 μm or more is skimmed milk powder and other nutrient components containing necessary nutrients as main components. For food, under sterile conditions,
Orally administered after uniformly adding and mixing. The dose of cellulose was 9 g / day on the 3rd day and 12 g / day on the 4th day and thereafter. Improvement of diarrhea symptoms was observed after the 5th day,
By day, she recovered to a loose stool condition similar to normal stool. In addition, the general findings were also improved with the improvement of diarrhea.
【0027】(対照例 2、臨床試験 2)実施例3で
使用したセルロ−スの200ミクロン〜5ミクロン区分
を分取した残余の篩分未通過区分を実施例3と同一組成
の濃厚栄養流動食に添加、混合した調製物を、第8日目
および第9日目の同一の患者に投与した。第8日目の投
与時には患者は口中の異物感を訴えつつも、所定量の栄
養流動食を摂取したが、第9日目の投与時には異物感を
理由に辛うじて約半量を摂取するにとどまった。 (Comparative Example 2, clinical test 2) The remaining non-passage fraction of the 200 μm to 5 μm fraction of the cellulose used in Example 3 was taken as the concentrated nutrient flow of the same composition as in Example 3. The preparation added to the diet and mixed was administered to the same patient on days 8 and 9. At the time of administration on the 8th day, the patient complained of a foreign body sensation in the mouth, but ingested a prescribed amount of nutritional liquid food, but at the time of the administration on the 9th day, the patient barely took about half the amount due to the foreign body sensation. .
【0028】第8日は正常便に類する軟便状態を維持し
たが第9日目および第10日目には下痢の症状を呈した
ので、第10日目以降は実施例3と同一の栄養流動食調
製物を所定量、投与した。第11日目以降は軟便状態に
回復し、下痢症状の改善を認めた。On the 8th day, loose stools similar to normal stools were maintained, but on the 9th day and the 10th day, diarrhea was exhibited. Therefore, from the 10th day onward, the same nutrient flux as in Example 3 was applied. A prescribed amount of food preparation was administered. From the 11th day onward, the patient recovered to loose stools, and improvement in diarrhea was noted.
【0029】(実施例 4、予防改善剤の調製 1)ア
ミノ酸混合物、脂質、糖、ビタミン類および ミネラル
類を主成分とする濃厚栄養流動食 「メディエフ リキ
ッド」 [商品名:味の素(株)製品] 1Kgに食品
添加物純度の200ミクロン以下、5ミクロン以上の粒
径を有するセルロ−ス粉末 50gを少量ずつ分割して
混合後、撹拌して均一な流動懸濁物を取得した。混合に
は、無菌条件下、外部を氷水で冷却した大型のワ−リン
グ ブレンダ−内で、1分間、高速回転撹拌する方法に
よった。取得した流動懸濁物を、約200ml宛、無菌
状態にある縦長の透明ガラス容器に分注し密封後、内部
温度5度Cに保持してある冷蔵庫内に、2日間保存し
た。2日後に室内に取り出し、室温に至るまで放置し
た。内容物に沈殿物の発生あるいは成分の分離は認めら
れなかった。 (Example 4, preparation of preventive and ameliorating agent 1) Concentrated nutrition liquid food "Medief Liquid" containing an amino acid mixture, lipid, sugar, vitamins and minerals as main components [Product name: Ajinomoto Co., Inc. product] 50 g of cellulose powder having a particle size of food additive purity of not more than 200 μm and not more than 5 μm was divided into 1 kg and mixed little by little and stirred to obtain a uniform fluid suspension. The mixing was carried out by aseptic stirring in a large Waring blender whose outside was cooled with ice water for 1 minute at a high speed. The obtained fluidized suspension was dispensed in an aseptic vertical transparent glass container in an amount of about 200 ml, sealed, and then stored in a refrigerator kept at an internal temperature of 5 ° C. for 2 days. After 2 days, it was taken out of the room and left to reach room temperature. No precipitate was found in the contents or the components were not separated.
【0030】(実施例 5、予防改善剤の調製 2)実
施例 4のセルロ−ス粉末にかえて、酢酸菌 、アセト
バクタ− キシリナム (Acetobacter x
ylinum)を蔗糖培地に、撹拌条件下に培養し生成
したセルロ−ス膜を分取、乾燥後、液体窒素冷却下、高
速粉砕して取得した微生物セルロ−スを添加して同様の
方法により均一な流動懸濁物を取得した。本懸濁物も、
実施例 4と同様な保存条件、保存期間内には、沈殿物
の発生あるいは成分の分離などは認められなかった。 (Example 5 : Preparation of preventive / improving agent 2) In place of the cellulose powder of Example 4, acetic acid bacteria, Acetobacter xylinum (Acetobacter x)
(ylinum) is cultured in a sucrose medium under stirring conditions, and the produced cellulose membrane is collected, dried, and then added with microbial cellulose obtained by high-speed crushing under liquid nitrogen cooling, and homogenized by the same method. A fluid suspension was obtained. This suspension also
Under the same storage conditions and storage period as in Example 4, no precipitation or separation of components was observed.
【0031】(対照例 3、予防改善剤の調製 3)実
施例4の方法に準じ、200ミクロン〜5ミクロン区分
を分取した残余の篩分未通過区分のセルロ−ス粉末を均
一に混合した濃厚栄養流動食調製物を取得した。該調製
物を 実施例4の保存方法に準じて保存したところ、翌
朝、冷蔵庫内で容器内容物の上層部または下層部に状態
の変化が認められ、室内に取り出し室温に至るまで放置
したところ、下層部、底部に絮状沈殿の発生を認めた。 (Comparative Example 3, Preparation of preventive and ameliorating agent 3) According to the method of Example 4, the remaining cellulose powder of the 200 μm to 5 μm fractions, which was not passed through the sieve fraction, was uniformly mixed. A concentrated nutrient liquid food preparation was obtained. When the preparation was stored according to the storage method of Example 4, a change in state was observed in the upper layer or the lower layer of the container contents in the refrigerator the next morning, and when the container was taken out indoors and left to reach room temperature, Generation of a wavy precipitate was observed in the lower layer and bottom.
【0032】[0032]
【発明の効果】本発明の下痢予防改善剤、下痢予防改善
食品および下痢予防改善飼料を、下痢症状を呈する患者
または動物に投与する時は、下痢症状を速やかに改善で
きる。特に経腸栄養剤、濃厚栄養流動食の投与時に、屡
々、発生する下痢の予防および改善に顕著な効果を認め
る。EFFECTS OF THE INVENTION When the diarrhea prevention / improvement agent, diarrhea prevention / improvement food and diarrhea prevention / improvement feed of the present invention are administered to a patient or animal exhibiting diarrhea symptoms, the diarrhea symptoms can be rapidly improved. In particular, a remarkable effect is often observed in the prevention and amelioration of diarrhea that often occurs during the administration of enteral nutritional supplements and concentrated liquid diets.
Claims (12)
防改善剤。1. A preventive and / or preventive agent for diarrhea containing cellulose powder as an active ingredient.
以上のセルロース粉末を有効成分とする下痢予防改善
剤。2. A diarrhea preventive and ameliorating agent comprising a cellulose powder having a particle diameter of 200 microns or less and 5 microns or more as an active ingredient.
上のセルロース粉末を全セルロース粉末の75%以上含
むことを特徴とする下痢予防改善剤。3. A preventive and / or preventive agent for diarrhea, which comprises cellulose powder having a particle size of 200 μm or less and 5 μm or more in an amount of 75% or more of the total cellulose powder.
とを特徴とする請求項1〜3の何れかに記載の下痢予防
改善剤。4. The agent for preventing and improving diarrhea according to claim 1, wherein the cellulose powder is derived from a plant.
ことを特徴とする請求項1〜3の何れかに記載の下痢予
防改善剤。5. The agent for improving and preventing diarrhea according to claim 1, wherein the cellulose powder is derived from a microorganism.
含有することを特徴とする請求項1〜4の何れかに記載
の下痢予防改善剤。6. The diarrhea preventive and ameliorating agent according to claim 1, wherein the cellulose powder contains hemicellulose.
予防改善剤を分散・配合させたことを特徴とする下痢予
防改善剤。7. A diarrhea prevention-improving agent comprising the diarrhea prevention-improving agent according to any one of claims 1 to 6 dispersed and mixed therein.
おいて、 前記請求項1〜6の何れかに記載の下痢予防改善剤を均
一に分散・配合させたことを特徴とする下痢予防改善
剤。8. The diarrhea prevention-improving agent according to claim 7, wherein the diarrhea prevention-improving agent according to any one of claims 1 to 6 is uniformly dispersed and blended. Agent.
予防改善剤を食品中に分散・配合させたことを特徴とす
る下痢予防改善食品。9. A diarrhea prevention-improving food, comprising the diarrhea prevention-improving agent according to any one of claims 1 to 6 dispersed and mixed in the food.
品において、 前記請求項1〜6の何れかに記載の下痢予防改善剤を食
品中に均一に分散・配合させたことを特徴とする下痢予
防改善食品。10. The diarrhea prevention-improving food according to claim 9, wherein the diarrhea prevention-improving agent according to any one of claims 1 to 6 is uniformly dispersed and mixed in the food. Diarrhea preventive improvement food.
痢予防改善剤を飼料中に分散・配合させたことを特徴と
する下痢予防改善飼料。11. A diarrhea-preventing and improving feed comprising the diarrhea-preventing and improving agent according to any one of claims 1 to 6 dispersed and mixed in the feed.
飼料において、 前記請求項1〜6の何れかに記載の下痢予防改善剤を飼
料中に均一に分散・配合させたことを特徴とする下痢予
防改善飼料。12. The diarrhea prevention-improving feed according to claim 11, wherein the diarrhea prevention-improving agent according to any one of claims 1 to 6 is uniformly dispersed and mixed in the feed. Diarrhea prevention feed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5029602A JPH06219953A (en) | 1993-01-27 | 1993-01-27 | Medicine for preventing and improving diarrhea, food for preventing and improving diarrhea and feed for preventing and improving scours |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5029602A JPH06219953A (en) | 1993-01-27 | 1993-01-27 | Medicine for preventing and improving diarrhea, food for preventing and improving diarrhea and feed for preventing and improving scours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06219953A true JPH06219953A (en) | 1994-08-09 |
Family
ID=12280621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5029602A Pending JPH06219953A (en) | 1993-01-27 | 1993-01-27 | Medicine for preventing and improving diarrhea, food for preventing and improving diarrhea and feed for preventing and improving scours |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06219953A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003150A1 (en) * | 1994-07-21 | 1996-02-08 | The University Of Montana | Compositions containing hemicelluloses and polyphenols for treating gastrointestinal disorders |
| CN115337288A (en) * | 2021-05-13 | 2022-11-15 | 陈昭诚 | Compositions comprising fibers formed from beta-1-4-glucan |
-
1993
- 1993-01-27 JP JP5029602A patent/JPH06219953A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003150A1 (en) * | 1994-07-21 | 1996-02-08 | The University Of Montana | Compositions containing hemicelluloses and polyphenols for treating gastrointestinal disorders |
| US5614501A (en) * | 1994-07-21 | 1997-03-25 | The University Of Montana | Compositions and methods for animal husbandry and for treating gastrointestinal disorders |
| US6087092A (en) * | 1994-07-21 | 2000-07-11 | University Of Montana | Compositions and methods for animal husbandry and for treating gastrointestinal disorders |
| CN115337288A (en) * | 2021-05-13 | 2022-11-15 | 陈昭诚 | Compositions comprising fibers formed from beta-1-4-glucan |
| EP4088726A1 (en) * | 2021-05-13 | 2022-11-16 | Chao-Cheng Chen | Composition for use in preventing or treating diarrhea, constipation or irritable bowel syndrome with fibers formed of beta-1-4-glucan |
| CN115337288B (en) * | 2021-05-13 | 2025-10-14 | 陈昭诚 | Compositions comprising fibers formed from beta-1-4-glucan |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6245326B1 (en) | Health supplement | |
| KR100516532B1 (en) | Inulin Products with Improved Nutritional Properties | |
| US7101553B2 (en) | Immune response enhancement methods | |
| WO2019112054A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
| EP0382355B1 (en) | Growth promoting agent for bacteria containing pullulan with or without dextran | |
| JP2006512295A (en) | Novel uses of carbohydrates and compositions | |
| DE60022513T2 (en) | USE OF FATTY ACID DERIVATES IN NASAL GASTRALE ENTERAL FORMULATIONS | |
| Gupta et al. | Xylooligosaccharide-a valuable material from waste to taste: a review | |
| US20230068996A1 (en) | Formula with galactomannan gum and non digestible oligosaccharides | |
| JPH09194384A (en) | Mineral absorption accelerating agent | |
| JP4771882B2 (en) | Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same | |
| JPH03151854A (en) | Intestinal harmful putrefaction product reducing agent | |
| WO2001016145A1 (en) | Immunopotentiating compositions | |
| JPH05304929A (en) | Liquid or fluid food | |
| WO2012133533A1 (en) | Agent for improving or maintaining qol | |
| JP5214978B2 (en) | Composition having blood pressure lowering action and / or elevation suppressing action and food and drink containing the same | |
| JP2000245391A (en) | healthy food | |
| JP4054697B2 (en) | Constipation improving agent | |
| JPH06219953A (en) | Medicine for preventing and improving diarrhea, food for preventing and improving diarrhea and feed for preventing and improving scours | |
| JPH09154535A (en) | Natto (fermented soybean)-containing composition | |
| KR100362025B1 (en) | Tumor-angiogenesis inhibitor and pharmaceutical composition | |
| US20120165289A1 (en) | Treatment | |
| JP3285959B2 (en) | Liquid preparation nutritional food for long-term medical care patients | |
| CN112806577A (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| JP2001316274A (en) | Tube feeding agent and method for producing the same |